^
Association details:
| Biomarker: | HER-2 overexpression |
|---|---|
| Cancer: | Biliary Tract Cancer |
| Drug: | zanidatamab (ZW25) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study. Add to Collection
Published date:
01/11/2021
Excerpt:
Among patients evaluable for response (n = 17), the confirmed ORR was 47% (n = 8; 95% confidence interval [CI]: 23, 72), the disease control rate was 65% (n = 11; 95% CI: 38, 86) and the median duration of response was 6.6 months (95% CI: 3.2, not estimable)....Zanidatamab is well tolerated with promising and durable anti-tumor activity in patients with HER2 overexpressing BTC.
Trial ID:
